The American College of Obstetricians and Gynecologists has published ACOG Clinical Practice Guideline No. 13, an evidence-graded update covering hot flashes and night sweats (vasomotor symptoms), sleep disturbance and mood symptoms during perimenopause and menopause. Its indexed record states that the guideline evaluates pharmacologic and nonpharmacologic interventions.
According to ACOOG's professional endorsement of the guideline, the guidance replaces ACOG's 2014 bulletin and includes hormonal, nonhormonal pharmacologic and nonpharmacologic routes within shared decision-making. The endorsement says symptoms, age, medical history, individual risks and personal goals belong in that discussion. The practical conclusion is that several evidence-based approaches may be considered, while no article can diagnose a symptom or identify the right treatment for an individual reader.
Start with the symptom changing daily life
“Menopause symptoms” can be too broad a phrase to guide a focused consultation. Hot flashes or night sweats may interrupt work, travel, exercise or dinner. Broken sleep may be the chief problem; for someone else, a change in mood may be more pressing. A useful starting point is simply to describe the main disturbance clearly, without trying to give it a diagnosis.
When did the symptom begin? How often does it occur? What part of the day or night does it disturb? Which activity, relationship or responsibility has become harder? These observations turn a vague sense of feeling unlike oneself into practical information for a clinician to explore. They also keep the consultation connected to quality of life, rather than to a generic score or a protocol seen online.
More than one evidence-based route
The three broad route labels are useful because they keep the conversation open without becoming a treatment catalogue. A reader can ask which categories are relevant to discuss and what evidence supports the specific option raised. Detailed decisions still belong in an individual consultation.
This article deliberately stays at category level. It does not name medicines, doses or formulations, and it does not present one route as the default. The new guidance is most helpful here as a map of the available kinds of conversation, rather than a consumer checklist.
Why personal history changes the decision
Shared decision-making changes the structure of the conversation. A reader can move away from the abstract question “Which treatment is best?” and ask instead: Which symptom matters most? What details from my history are relevant? What goals should guide the discussion? The answers belong in a consultation, not in a self-administered eligibility test.
The conversation can then move from the most disruptive symptom to the benefits, risks and uncertainties that need explanation. It can also establish what would be reviewed later and when another discussion would be useful. Those are questions to settle with a clinician, not instructions to start, stop, switch or combine any treatment.
Use the guideline as a marketing filter
The Associated Press's independent account of the new menopause guidance describes it as the first major update in about 12 years, confirms that several treatment routes exist and notes the problem of misinformation around menopause care. That makes evidence checking a practical part of the reader's preparation.
For any claim encountered online, ask what intervention and outcome are actually being discussed, who was studied and whether the source points to current professional guidance or a defined piece of research. Then take the unanswered questions to a qualified clinician. This filter does not establish that a claim is true or false; it helps reveal what still needs verification.
Questions worth taking to a consultation
A short list can keep the conversation anchored in quality of life:
- Which symptom should we assess first?
- Which treatment categories could reasonably be discussed in light of my age, history, individual risks and goals?
- What benefit would be realistic for the symptom that concerns me most?
- What side effects and uncertainties should be part of the discussion?
- How and when would the plan be reviewed?
The value of the new guidance lies in taking disruptive hot flashes, poor sleep and mood symptoms seriously while preserving individual judgement. A well-prepared appointment begins with the life being disrupted and ends with a clearer understanding of the evidence, its limits and the next questions to ask.